Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Shutterstock/Lestertair

Emerade adrenaline pen recalled by health regulator

Anyone who uses the pens are being told to return them to pharmacies.

A BATCH OF adrenaline pens used to treat allergic reactions is being recalled. 

The recall of the Emerade pens was announced today by the Health Products Regulatory Authority (HPRA).

The decision to recall a batch of the pens was made after some Emerade pens in other countries failed to produce an injection and failed to activate, with the potential for a blocked needle.

The pen is an emergency treatment for anaphylaxis. 

The recall covers batches of: 

  • 150mcg pre-filled Emerade pens
  • 300mcg pre-filled Emerade pens
  • 500mcg pre-filled Emerade pens

Anyone who has an Emerade pen has been told by HPRA to return it to their local pharmacy and get it replaced with an alternative product. 

The cause of the activation failure is unknown, as is rate of the defect in the pen.

Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

Close
7 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel

     
    JournalTv
    News in 60 seconds